Regeneron plots $800M New York production push—along with 1,500 new jobs

Regeneron is humming along on the strength of flagship eye med Eylea and fast-launching immunology drug Dupixent. Now, the drugmaker is dropping $800 million into its New York operations to keep up with the growth. Regeneron is planning a statewide expansion of its production facilities, including the final phase of its East Greenbush site.